Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

Martina Klein

Karl-Heinz Schlemmer

Lars Bärfacker

Barbara Albrecht-Küpper

Johannes-Peter Stasch

Andreas Knorr

Rudolf Schohe-Loop

Joachim Schuhmacher

Peter Kolkhof

Rolf Grosser

Thomas Lampe

Alexander Hillisch

Raimund Kast

Mario Jeske

Eva-Maria Becker

Friederike Stoll

Hartmut Beck

Gunter Karig

Klaus Münter

Elke Hartmann

Mark Meininghaus

Volkhart Min-Jian Li

Klemens Lustig

Hanna Tinel

Metin Akbaba

Adam Nitsche

Bernd Riedl

Daniel Meibom

Stefan Golz

Ulf Brüggemeier

Franz Von Nussbaum

Peter Sandner

Andreas Geerts

Peter Ellinghaus

Joachim Hütter

Sonja Steppan

Friedrich Grimminger

Olaf Christensen

Holger Summer

Reiner Frey

Hendrik Milting

Michael Seewald

Donatella D'Urso

Donatella D'urso

Barbara Albrecht-Kuepper

Klaus Muenter

Ralph Schermuly

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use

Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof

The present application relates to novel, cyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.

Cyclically substituted furopyrimidine derivatives and use thereof

The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

Compounds for treating pulmonary hypertension

The present application relates to novel, acyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.

Acyclically substituted furopyrimidine derivatives and use thereof

The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

LTBP2 as a biomarker and diagnostic target

Growing community of inventors

Düsseldorf, Germany

Martina Klein